DANAHER CORP: management transactions · United States · SEC (Form 4)

About DANAHER CORP

Danaher Corp /DE/ (ticker: DHR) is a major U.S.-listed company traded on the NYSE in the United States. It has evolved from a diversified industrial acquirer into a focused science-and-technology platform centered on life sciences, diagnostics, and biotechnology. The company is headquartered in Washington, DC, and operates globally across 50 countries and roughly 700 locations, reflecting a broad international footprint that supports manufacturing, R&D, sales, and service activities. Founded in 1984, Danaher built its reputation through disciplined acquisitions, operational excellence, and the Danaher Business System, which remains a core part of how the group integrates and improves acquired businesses. ([danaher.com](https://www.danaher.com/global-locations?utm_source=openai)) Danaher currently reports three main operating platforms: Biotechnology, Diagnostics, and Life Sciences. Biotechnology includes leading brands such as Cytiva and Pall, providing technologies, consumables, and services that support bioprocessing, therapeutic development, and manufacturing. Diagnostics offers clinical testing and patient-care solutions designed to improve diagnostic confidence and speed, while Life Sciences covers scientific instruments, reagents, software, and workflow solutions used in research, drug development, and biological analysis. This structure gives Danaher exposure to multiple steps in the healthcare value chain, from basic research to large-scale biomanufacturing and clinical diagnostics. ([danaher.com](https://danaher.com/our-businesses?utm_source=openai)) From a competitive standpoint, Danaher is recognized for strong market positions, well-known brands, recurring consumables revenue, installed-base advantages, and a reputation for execution in complex, regulated end markets. The company also highlights the scale of its biotechnology franchise, stating that its biotechnology businesses support a very large share of approved monoclonal antibody production worldwide, underscoring its importance in the biopharma supply chain. ([danaher.com](https://www.danaher.com/about-danaher?utm_source=openai)) Recent developments point to both operational momentum and portfolio expansion. In January 2026, Danaher reported full-year 2025 results, including $24.6 billion in revenue and 3.0% year-over-year revenue growth. In February 2026, the company announced an agreement to acquire Masimo, a move aimed at strengthening its specialty diagnostics capabilities. For investors, DHR remains a high-quality healthcare and tools compounder with structural exposure to long-term growth in bioprocessing, diagnostics, and life sciences, supported by a long-standing capital-allocation framework and global reach. ([investors.danaher.com](https://investors.danaher.com/2026-01-28-Danaher-Reports-Fourth-Quarter-and-Full-Year-2025-Results?utm_source=openai))